PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lindsey E. Roeker, MD
Memorial Sloan-Kettering Cancer Center, New York, NY
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Epworth Healthcare
East Melbourne, Victoria, Australia
Recruiting - One Clinical Research
Perth, Western Australia, Australia
Recruiting
- Ruijin Hospital
Shanghai, China
Recruiting
- Norton Cancer Institute
Louisville, Kentucky, United States
Recruiting - Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Not, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Nov 2021
- Primary completion
- 31 Jul 2023
- Completion
- 31 Jan 2024
- Last update posted
- 28 Mar 2022
- Registered enrollment
- 110
- Registry id
- NCT05003141
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.